Novel Foods 2026: Strategic Use of the Union List as a Competitive Advantage

Innovation in food ingredients is moving quickly across algae-derived compounds, fungal biomass, precision-fermented carbohydrates, plant extracts and new nutrient sources. In the European Union, commercial success depends on a legal question that is frequently addressed too late: does the ingredient placed on the market fall under the category of “novel foods”?

Regulation (EU) 2015/2283 defines a novel food to the absence of significant human consumption in the EU before 15 May 1997 and requires authorisation before market entry. Commission Implementing Regulation (EU) 2017/2470 contains the Union List. The European Commission describes that list as the compilation of authorised novel foods, including their conditions of use, labelling requirements and specifications. Authorisations are generally available to economic operators that comply with the relevant entry, subject to any applicant-specific data protection.

This structure creates a distinct form of regulatory competition. The value of an authorisation lies in the legal perimeter drawn around the ingredient, the permitted applications and the evidence supporting its safety. Companies that understand those boundaries can design ingredients and dossiers with a stronger commercial position, assess competitor freedom to operate with greater precision and build supply agreements around verifiable regulatory eligibility.

The Union List as a Market Access Instrument

The Union List should be read as an operating framework for commercialisation. Its entries determine which novel food may be sold, where it may be used, at what level, for which population, under which labelling conditions and within which compositional parameters.

The pace of updates illustrates the range of innovation passing through the system. The Commission’s 2026 updates include defatted rapeseed powder, a strain-specific form of lacto-N-tetraose, inulin-propionate ester and rhamnogalacturonan-I enriched carrot extract. Recent authorisations and amendments also cover vitamin D2 mushroom powders, Schizochytrium oils, beta-glucan from Euglena gracilis microalgae, astaxanthin-rich oleoresin from Haematococcus pluvialis and chromium-containing yeast biomass.

Each entry is a regulatory asset with defined dimensions. Table 1 of the Union List sets out authorised food categories, maximum levels, additional labelling requirements, other conditions and any applicable data protection. Table 2 provides the specification, which may include biological source, strain, chemical identity, production process, physical form, purity, nutrient composition, contaminants, microbiological criteria and analytical parameters. The commercial ingredient must remain inside this combined perimeter.

This has practical consequences. A familiar ingredient name does not establish compliance. “Mushroom powder”, “algal oil” or “fungal biomass” may describe several materials with different species, strains, processes, concentrations and impurity profiles. A supplier’s certificate of analysis may demonstrate selected numerical results, yet still leave unresolved questions about source identity, processing history, analytical methods or authorised uses.

Specification Boundaries Define the Addressable Market

“Specification boundary” is a useful strategic term, although it is not defined in the Regulation. It describes the legal and scientific limits that determine whether a commercial material corresponds to an authorised novel food.

The first boundary is identity. For botanical, algal and fungal ingredients, this can include genus, species, plant or organism part, culture collection reference and growth substrate. For fermentation-derived ingredients, the production organism and strain lineage may be central.

The 2026 authorisation of lacto-N-tetraose produced by a derivative of Escherichia coli K-12 MG1655 sits alongside earlier authorisations for lacto-N-tetraose produced using other E. coli strains. The molecule has the same general identity, while the production organism, process data and impurity profile support a distinct authorised entry.

The second boundary is production. Extraction solvent, irradiation conditions, fermentation controls, purification sequence, enzyme use, drying method and inactivation step can influence composition and safety. A change that appears operationally minor may alter the relationship between the commercial material and the listed definition. Companies should therefore evaluate process changes through a regulatory change-control procedure before implementation.

The third boundary is composition. Minimum active-content levels, maximum residuals, protein, carbohydrate, fat, moisture, ash, contaminants and microbiological limits can all determine eligibility.

The 2024 amendment for one vitamin D2 mushroom powder changed the specification to permit total carbohydrate up to 60 percent. The Commission’s reasoning referred to practical uncertainty in determining dietary fibre and carbohydrate separately and noted the carbohydrate limits used for other authorised powders. This amendment illustrates how specification design affects batch release, manufacturing yield and the range of material that can legally be supplied under an entry.

The fourth boundary is use. An ingredient authorised in food supplements is not automatically authorised in beverages, meal replacements, conventional foods or foods for special medical purposes. Maximum levels can differ by category and target population. Conditions may also restrict use by children, pregnant or lactating women, or consumers using other products containing the same ingredient on the same day.

EFSA’s exposure assessment depends on the proposed categories, levels and population groups. The final Union List entry converts that assessment into enforceable conditions.

Data Protection Creates a Defined Exclusivity Window

Articles 26 and 27 of Regulation (EU) 2015/2283 allow an applicant to request protection for newly developed scientific evidence or proprietary scientific data. The applicant must substantiate that the data were proprietary when the application was submitted, that it held an exclusive right of reference and that the novel food could not have been authorised without those data.

When the conditions are met, the protected evidence cannot be used for the benefit of a subsequent applicant without agreement for five years. The initial applicant is identified in the Union List entry.

This mechanism can create a valuable period of regulatory exclusivity. Its scope remains tied to the authorised novel food and the protected evidence. It does not create ownership of an ingredient category, biological species, chemical molecule or consumer benefit. A later applicant may seek authorisation using independently generated or legally accessible evidence. A competitor may also develop a materially distinct ingredient that requires its own safety assessment and Union List entry.

The 2026 lacto-N-tetraose authorisation provides a clear example. The Commission concluded that EFSA’s safety assessment depended on proprietary information concerning identity, the genetically modified production strain, production, composition, stability, toxicology, metabolism and allergenicity.

Inbiose N.V. received applicant-specific authorisation from 16 March 2026, with protection running to 16 March 2031. The regulation also states that another applicant may obtain authorisation without reference to the protected data or with the applicant’s agreement.

Rhamnogalacturonan-I enriched carrot extract provides another current example. Commission Implementing Regulation (EU) 2026/1306 protects data on identity, composition and toxicology and identifies NutriLeads B.V. as the authorised operator during the protection period, which ends on 2 July 2031.

The final legal designation also changed from “carrot fibre” to “carrot extract” because EFSA had not assessed whether the material met the legal definition of dietary fibre. That naming decision shows how scientific characterisation, food information law and commercial positioning converge within a novel food authorisation.

The July 2026 authorisation of Rhizomucor pusillus mycelium continues this pattern in fungal innovation. Commission Implementing Regulation (EU) 2026/1507 authorises The Protein Brewery B.V. to place the novel food on the EU market for five years from 26 July 2026, subject to the possibility of a subsequent authorisation based on independently generated or lawfully accessible data. The scientific data protected under Article 26(2) of Regulation (EU) 2015/2283 may not be used for the benefit of another applicant during this period without the company’s agreement. The regulation was published on 6 July 2026 and enters into force on 26 July 2026.

Designing a Defensible Authorisation

A defensible position begins with deliberate specification architecture. The proposed specification must describe the material closely enough to support a reliable safety conclusion and distinguish it from uncontrolled variants. It must also accommodate normal manufacturing variability.

Limits that are disconnected from validated process capability can create recurring non-conformities. Broad ranges may increase the scientific burden because the safety assessment must cover the full proposed material.

The strongest parameters usually have three qualities. They are scientifically relevant, routinely measurable and linked to the applicant’s manufacturing knowledge. Examples include a characteristic marker profile, a defined ratio of constituents, strain-specific production, a validated purification endpoint or impurity limits reflecting a controlled process.

These parameters can make the authorised entry commercially meaningful while giving quality teams objective release criteria.

Analytical method strategy also matters. A numerical specification has limited operational value when laboratories use methods that produce systematically different results. The dossier should establish method suitability, performance characteristics, sample preparation, reference standards and units on a dry-weight or as-is basis. Contract laboratories, manufacturing sites and customers should be aligned before commercial launch.

Data ownership needs equal attention. Study contracts should establish ownership, rights of reference, access to raw data and the ability to submit complete study reports. Applicants should identify which studies are newly developed, which information is publicly available and which evidence is expected to be essential to EFSA’s conclusion.

EFSA also requires studies commissioned or carried out after 27 March 2021 to be notified before they start. Non-confidential application information is made public during the assessment process. These transparency requirements influence study planning, confidentiality review and the timing of intellectual-property decisions.

Using Existing Entries Without Assuming Freedom to Operate

For downstream brands, the Union List can shorten market entry when an existing generic authorisation covers the intended ingredient. That opportunity requires a structured conformity assessment.

The assessment should map the supplier’s material against every element of the entry. Identity and source should be confirmed through taxonomic, strain or chemical documentation. The manufacturing process should be compared with any process description in the specification. Several representative batches should be tested against all compositional and microbiological criteria using suitable methods.

Intended food categories, maximum levels, daily intake and target populations should then be checked against Table 1. Product labels must reproduce the required designation and any mandatory warnings.

Data protection status requires a separate review. A distributor may offer a material that appears analytically equivalent to a protected novel food while lacking the protected applicant’s consent or an independent authorisation. Customers should request a clear regulatory supply statement identifying the applicable Union List entry, the authorised operator where relevant and the legal basis for supply during the protection period.

Contract terms can reinforce this control. Supply agreements may address continuing conformity with the Union List, notification of process or specification changes, access to supporting documentation, audit rights, regulatory cooperation, indemnities and obligations following an amendment or expiry of data protection. These provisions convert regulatory fit into an ongoing supplier responsibility.

Managing the Authorisation as a Lifecycle Asset

The Union List is dynamic. Companies can apply to change specifications, extend conditions of use, revise labelling requirements or add target populations. Recent amendments concerning vitamin D2 mushroom powder, Haematococcus pluvialis astaxanthin oleoresin, Schizochytrium oils and chromium-containing yeast biomass show that authorisation strategy continues after initial approval.

A focused initial use can support an earlier commercial launch, followed by extensions built on additional exposure or safety evidence. A specification amendment can reduce avoidable batch failures or incorporate a validated manufacturing improvement. Each change should be assessed for scientific burden, commercial value, timing and possible effects on protected data.

Authorisation also sits within a wider compliance framework. Food information rules, supplement legislation, fortification rules, contaminant requirements and national notification procedures may still apply.

Novel food authorisation does not approve a nutrition or health claim. Claims used in labelling and advertising must comply with Regulation (EC) No 1924/2006 and the relevant authorised conditions.

A Strategic Decision Model for 2026

Companies developing innovative ingredients should connect regulatory design with commercial strategy from the beginning.

The first question concerns legal identity. What exact material will be sold, and which source, process and compositional features define it?

The second concerns evidence. Which safety uncertainties must be addressed, which studies will be proprietary, and can the Article 26 criteria realistically be met?

The third concerns market scope. Which food categories, populations and use levels create a commercially viable launch case while remaining supportable through exposure and safety data?

The fourth question concerns defensibility. Teams should identify which specification parameters reflect unique process capability, which parameters can be monitored at scale and where competitors could develop a separate entry through a different strain, process or composition.

The fifth concerns lifecycle value. A roadmap should anticipate future extensions, specification amendments, new formats, additional populations and the end of the five-year protection period.

This analysis should involve regulatory, scientific, manufacturing, quality, intellectual-property, commercial and procurement functions. Decisions made during process development can determine the final specification. Decisions made in study contracting can determine whether data protection is available. Decisions made in the proposed conditions of use can define the addressable market for years.

Turning Regulatory Detail into Market Advantage

The Union List has become a strategic map of the European novel food market. It identifies authorised opportunities, exposes technical boundaries, records applicant-specific protection and shows where competitors have built regulatory positions around particular strains, processes and compositions.

For ingredient developers, the opportunity lies in aligning scientific evidence, specification design and data ownership with a clear commercial model. For food and supplement brands, advantage comes from precise entry matching, disciplined supplier due diligence and early identification of protected authorisations. For investors and transaction teams, the Union List provides a basis for testing whether claimed market access is broad, narrow, exclusive, transferable through contract or dependent on a single manufacturing process.

In 2026, successful novel food strategy requires control of the details contained within the authorisation. Those details determine who can enter the market, what can be sold, how the ingredient may be used and how durable the resulting position may become.